Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9.

PMID:
31180194
2.

Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes.

Baker RL, Rihanek M, Hohenstein AC, Nakayama M, Michels A, Gottlieb PA, Haskins K, Delong T.

Diabetes. 2019 Sep;68(9):1830-1840. doi: 10.2337/db19-0128. Epub 2019 Jun 7.

PMID:
31175101
3.

Shear stress-induced nuclear shrinkage through activation of Piezo1 channels in epithelial cells.

Jetta D, Gottlieb PA, Verma D, Sachs F, Hua SZ.

J Cell Sci. 2019 Jun 12;132(11). pii: jcs226076. doi: 10.1242/jcs.226076.

PMID:
31076516
4.

Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor.

Vaitaitis GM, Rihanek M, Alkanani AK, Waid DM, Gottlieb PA, Wagner DH; Type 1 Diabetes TrialNet Study Group.

J Clin Endocrinol Metab. 2019 May 7. pii: jc.2019-00364. doi: 10.1210/jc.2019-00364. [Epub ahead of print]

PMID:
31063181
5.

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.

PMID:
30967424
6.

Elevated PTEN expression maintains anergy in human B cells and reveals unexpectedly high repertoire autoreactivity.

Smith MJ, Ford BR, Rihanek M, Coleman BM, Getahun A, Sarapura VD, Gottlieb PA, Cambier JC.

JCI Insight. 2019 Feb 7;4(3). pii: 123384. doi: 10.1172/jci.insight.123384. [Epub ahead of print]

7.

Rationally designed small molecules to prevent type 1 diabetes.

Ostrov DA, Gottlieb PA, Michels AW.

Curr Opin Endocrinol Diabetes Obes. 2019 Apr;26(2):90-95. doi: 10.1097/MED.0000000000000470.

PMID:
30694829
8.

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.

Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network.

Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19.

PMID:
30569273
9.

Functional analyses of heteromeric human PIEZO1 Channels.

Gnanasambandam R, Bae C, Ziegler L, Sachs F, Gottlieb PA.

PLoS One. 2018 Nov 21;13(11):e0207309. doi: 10.1371/journal.pone.0207309. eCollection 2018.

10.

Enantiomeric Aβ peptides inhibit the fluid shear stress response of PIEZO1.

Maneshi MM, Ziegler L, Sachs F, Hua SZ, Gottlieb PA.

Sci Rep. 2018 Sep 24;8(1):14267. doi: 10.1038/s41598-018-32572-2.

11.

Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk for Type 1 Diabetes.

Gavin PG, Mullaney JA, Loo D, Cao KL, Gottlieb PA, Hill MM, Zipris D, Hamilton-Williams EE.

Diabetes Care. 2018 Oct;41(10):2178-2186. doi: 10.2337/dc18-0777. Epub 2018 Aug 12.

12.

Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes.

Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2019 Feb;42(2):192-199. doi: 10.2337/dc18-0288. Epub 2018 Jul 30.

PMID:
30061316
13.

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.

14.

Learning From Past Failures of Oral Insulin Trials.

Michels AW, Gottlieb PA.

Diabetes. 2018 Jul;67(7):1211-1215. doi: 10.2337/dbi17-0043.

15.

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA.

Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16.

16.

Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes.

Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, Pöllinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW.

J Clin Invest. 2018 May 1;128(5):1888-1902. doi: 10.1172/JCI97739. Epub 2018 Apr 3.

17.

Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles.

Smith MJ, Rihanek M, Wasserfall C, Mathews CE, Atkinson MA, Gottlieb PA, Cambier JC.

Diabetes. 2018 Apr;67(4):697-703. doi: 10.2337/db17-0937. Epub 2018 Jan 17.

18.

Activation of thyroid antigen-reactive B cells in recent onset autoimmune thyroid disease patients.

Smith MJ, Rihanek M, Coleman BM, Gottlieb PA, Sarapura VD, Cambier JC.

J Autoimmun. 2018 May;89:82-89. doi: 10.1016/j.jaut.2017.12.001. Epub 2017 Dec 9.

19.

Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Dec;60(12):2540. doi: 10.1007/s00125-017-4446-5. No abstract available.

PMID:
28948305
20.

Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Nov;60(11):2139-2147. doi: 10.1007/s00125-017-4384-2. Epub 2017 Aug 2. Review. Erratum in: Diabetologia. 2017 Sep 26;:.

21.

Preface.

Gottlieb PA.

Curr Top Membr. 2017;79:xiii-xiv. doi: 10.1016/S1063-5823(17)30019-4. No abstract available.

PMID:
28728826
22.

A Microfluidic Approach for Studying Piezo Channels.

Maneshi MM, Gottlieb PA, Hua SZ.

Curr Top Membr. 2017;79:309-334. doi: 10.1016/bs.ctm.2016.11.005. Epub 2017 Jan 18. Review.

PMID:
28728822
23.

The Kinetics and the Permeation Properties of Piezo Channels.

Gnanasambandam R, Gottlieb PA, Sachs F.

Curr Top Membr. 2017;79:275-307. doi: 10.1016/bs.ctm.2016.11.004. Epub 2017 Jan 11. Review.

PMID:
28728821
24.

A Tour de Force: The Discovery, Properties, and Function of Piezo Channels.

Gottlieb PA.

Curr Top Membr. 2017;79:1-36. doi: 10.1016/bs.ctm.2016.11.007. Epub 2017 Jan 11. Review.

PMID:
28728814
25.

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.

Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569.

26.

Detection and Enrichment of Rare Antigen-specific B Cells for Analysis of Phenotype and Function.

Smith MJ, Packard TA, O'Neill SK, Hinman RM, Rihanek M, Gottlieb PA, Cambier JC.

J Vis Exp. 2017 Feb 16;(120). doi: 10.3791/55382.

27.

The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.

Sosenko JM, Yu L, Skyler JS, Krischer JP, Gottlieb PA, Boulware D, Miao D, Palmer JP, Steck AK.

Diabetes Technol Ther. 2017 Mar;19(3):183-187. doi: 10.1089/dia.2016.0243. Epub 2017 Feb 8.

28.

Mechanosensitive ion channel Piezo2 is inhibited by D-GsMTx4.

Alcaino C, Knutson K, Gottlieb PA, Farrugia G, Beyder A.

Channels (Austin). 2017 May 4;11(3):245-253. doi: 10.1080/19336950.2017.1279370. Epub 2017 Jan 13.

29.

Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.

Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, Jones KL, Gottlieb PA, Kappler JW, Tang Q, Roep BO, Atkinson MA, Mathews CE, Nakayama M.

Diabetes. 2017 Mar;66(3):722-734. doi: 10.2337/db16-1025. Epub 2016 Dec 5.

30.

Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA.

Diabetes. 2016 Dec;65(12):3765-3775. Epub 2016 Sep 26.

31.

Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.

Simmons KM, Gottlieb PA, Michels AW.

Curr Diab Rep. 2016 Oct;16(10):97. doi: 10.1007/s11892-016-0793-8. Review.

32.

Mechanosensitive ion channel Piezo2 is important for enterochromaffin cell response to mechanical forces.

Wang F, Knutson K, Alcaino C, Linden DR, Gibbons SJ, Kashyap P, Grover M, Oeckler R, Gottlieb PA, Li HJ, Leiter AB, Farrugia G, Beyder A.

J Physiol. 2017 Jan 1;595(1):79-91. doi: 10.1113/JP272718. Epub 2016 Aug 13.

33.

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.

Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR; ITN START Study Team.

Diabetologia. 2016 Jun;59(6):1153-61. doi: 10.1007/s00125-016-3917-4. Epub 2016 Apr 6.

34.

Human PIEZO1 Ion Channel Functions as a Split Protein.

Bae C, Suchyna TM, Ziegler L, Sachs F, Gottlieb PA.

PLoS One. 2016 Mar 10;11(3):e0151289. doi: 10.1371/journal.pone.0151289. eCollection 2016.

35.

Predominance of DR3 in Somali children with type 1 diabetes in the twin cities, Minnesota.

Sunni M, Noble JA, Yu L, Mahamed Z, Lane JA, Dhunkal AM, Bellin MD, Nathan B, Kyllo J, Abuzzahab MJ, Gottlieb PA, Babu S, Armstrong T, Moran A.

Pediatr Diabetes. 2017 Mar;18(2):136-142. doi: 10.1111/pedi.12369. Epub 2016 Feb 8.

PMID:
26854192
36.

Removal of the mechanoprotective influence of the cytoskeleton reveals PIEZO1 is gated by bilayer tension.

Cox CD, Bae C, Ziegler L, Hartley S, Nikolova-Krstevski V, Rohde PR, Ng CA, Sachs F, Gottlieb PA, Martinac B.

Nat Commun. 2016 Jan 20;7:10366. doi: 10.1038/ncomms10366.

37.

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. Review.

38.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Review.

39.

Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.

Loechelt BJ, Green M, Gottlieb PA, Blumberg E, Weinberg A, Quinlan S, Baden LR; Type 1 Diabetes TrialNet Study Group.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):198-204. doi: 10.1093/jpids/piu055. Epub 2014 Jun 26.

40.

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.

41.

What defines disease in an age of genetics and biomarkers?

Gottlieb PA.

Curr Opin Endocrinol Diabetes Obes. 2015 Aug;22(4):296-9. doi: 10.1097/MED.0000000000000172. Review.

PMID:
26087344
42.

Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes.

Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, Frank DN, Zipris D.

Diabetes. 2015 Oct;64(10):3510-20. doi: 10.2337/db14-1847. Epub 2015 Jun 11.

43.

Ionic Selectivity and Permeation Properties of Human PIEZO1 Channels.

Gnanasambandam R, Bae C, Gottlieb PA, Sachs F.

PLoS One. 2015 May 8;10(5):e0125503. doi: 10.1371/journal.pone.0125503. eCollection 2015.

44.

Development of Autoimmune-Mediated β Cell Failure After Total Pancreatectomy With Autologous Islet Transplantation.

Bellin MD, Moran A, Wilhelm JJ, O'Brien TD, Gottlieb PA, Yu L, Dunn TB.

Am J Transplant. 2015 Jul;15(7):1991-4. doi: 10.1111/ajt.13216. Epub 2015 Mar 12.

45.

Protonation of the human PIEZO1 ion channel stabilizes inactivation.

Bae C, Sachs F, Gottlieb PA.

J Biol Chem. 2015 Feb 20;290(8):5167-73. doi: 10.1074/jbc.M114.604033. Epub 2015 Jan 5.

46.

Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients.

Smith MJ, Packard TA, O'Neill SK, Henry Dunand CJ, Huang M, Fitzgerald-Miller L, Stowell D, Hinman RM, Wilson PC, Gottlieb PA, Cambier JC.

Diabetes. 2015 May;64(5):1703-12. doi: 10.2337/db13-1798. Epub 2014 Dec 18.

47.

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA.

J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15.

48.

Hereditary xerocytosis revisited.

Archer NM, Shmukler BE, Andolfo I, Vandorpe DH, Gnanasambandam R, Higgins JM, Rivera A, Fleming MD, Sachs F, Gottlieb PA, Iolascon A, Brugnara C, Alper SL, Nathan DG.

Am J Hematol. 2014 Dec;89(12):1142-6. doi: 10.1002/ajh.23799. Epub 2014 Jul 21. No abstract available.

49.

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.

Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P; DEFEND Investigator Group.

Diabetes Care. 2014 Oct;37(10):2746-54. doi: 10.2337/dc13-0327. Epub 2014 Jul 10.

50.

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR; START Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):306-16. doi: 10.1016/S2213-8587(13)70065-2. Epub 2013 Aug 28.

Supplemental Content

Loading ...
Support Center